

AMENDMENTS TO THE CLAIMS**Listing of Claims**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. **(Currently Amended)** A method of treating multiple myeloma in a subject, comprising administering Use of roscovitine, or a pharmaceutically acceptable salt thereof, to said subject in the preparation of a medicament for treating multiple myeloma.
2. **(Currently Amended)** The method of Use according to claim 1, further comprising administering wherein the roscovitine is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
3. **(Currently Amended)** The method of Use according to claim 1, or claim 2 wherein the roscovitine is administered in an amount sufficient to inhibit at least one CDK enzyme.
4. **(Currently Amended)** The method of Use according to claim 3, wherein the CDK enzyme is selected from the group consisting of CDK1, CDK2, CDK4, CDK7 and CDK9.
5. **(Currently Amended)** The method of Use according to claim 3, wherein the CDK enzyme is selected from CDK1 and or CDK2.
6. **(Currently Amended)** The method of Use according to claim 3, wherein the CDK enzyme is selected from CDK7 and or CDK9.
7. **(Currently Amended)** The method of Use according to any preceding claim 1, wherein the multiple myeloma is selected from the group consisting of IgA myeloma, IgG myeloma, IgD myeloma, IgE myeloma, Bence Jones myeloma and non-secretory myeloma.
8. **(Currently Amended)** The method of Use according to claim 7, wherein the multiple myeloma is IgA or IgG myeloma.

9. **(Currently Amended)** The method of Use according to any preceding claim 1, further comprising administering wherein the roscovitine is administered in combination with one or more other at least one additional antiproliferative agent[[s]].

10-18. **(Cancelled)**

19. **(Original)** A pharmaceutical composition comprising (i) roscovitine, or a pharmaceutically acceptable salt thereof; and optionally (ii) a pharmaceutically acceptable carrier, diluent or excipient, for use in the treatment of multiple myeloma.

20. **(Original)** A method of down regulating expression of an anti-apoptotic gene in multiple myeloma cells, the method comprising contacting the cells with roscovitine, or a pharmaceutically acceptable salt thereof.

21. **(Original)** A method of treating multiple myeloma in a subject, the method comprising administering roscovitine, or a pharmaceutically acceptable salt thereof, to the subject in an amount sufficient to down regulate the expression of an anti-apoptotic gene in the subject.

22. **(Currently Amended)** The method of claim 20, or 21 wherein the anti-apoptotic gene is Mcl-1.

23. **(Original)** A method of down-regulating Mcl-1 expression in multiple myeloma cells, said method comprising contacting said cells with roscovitine, or a pharmaceutically acceptable salt thereof.

24. **(Original)** A method of treating multiple myeloma in a subject, said method comprising administering roscovitine, or a pharmaceutically acceptable salt thereof, to the subject in an amount sufficient to down-regulate the expression of Mcl-1 in said subject.

25-26. **(Cancelled)**

27. **(New)** The method of claim 21, wherein the anti-apoptotic gene is Mcl-1.